Faculty

Back to Index
Axel Schonthal, PhD
Associate Professor of Molecular Microbiology & Immunology
Molecular Microbiology and Immunology
HMR 405A 2011 Zonal Avenue Health Sciences Campus Los Angeles
+1 323 442 1730

Overview

The Schonthal lab performs preclinical cancer research and pursues anticancer drug development. The main focus is on brain malignancies, which include primary brain cancers (such as glioblastoma) and secondary brain cancers (such as melanoma or breast cancer that has spread to the brain). The work is done in collaboration with Dr. Thomas Chen, Director of the USC Brain Tumor Group, and Dr. Florence Hofman from the Department of Pathology. This joint approach supports interdisciplinary efforts that translate laboratory findings to patient applications.

Publications

A perillyl alcohol-conjugated analog of 3-bromopyruvate without cellular uptake dependency on monocarboxylate transporter 1 and with activity in 3-BP-resistant tumor cells. Cancer Lett. 2017 Apr 24; 400:161-174. View in: PubMed

Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases. Int J Mol Sci. 2016; 17(9). View in: PubMed

A novel temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo. Cancer Lett. 2015 Mar 28; 358(2):144-51. View in: PubMed

Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy. Am J Cancer Res. 2015; 5(5):1580-93. View in: PubMed

Chemotherapeutic effect of a novel temozolomide analog on nasopharyngeal carcinoma in vitro and in vivo. J Biomed Sci. 2015; 22(1):71. View in: PubMed

A Novel Temozolomide-Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells In Vitro and Intracranial Triple-Negative Tumor Growth In Vivo. Mol Cancer Ther. 2014 May; 13(5):1181-93. View in: PubMed

Pharmacological targeting of endoplasmic reticulum stress signaling in cancer. Biochem Pharmacol. 2013 Mar 1; 85(5):653-66. View in: PubMed

Adverse effects of concentrated green tea extracts. Mol Nutr Food Res. 2011 Jun; 55(6):874-85. View in: PubMed

Exploiting cyclooxygenase-(in)dependent properties of COX-2 inhibitors for malignant glioma therapy. Anticancer Agents Med Chem. 2010 Jul; 10(6):450-61. View in: PubMed

Powered bySC CTSI